Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic.
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic, including that some aspects of radiation treatment supervision will go away.
Transcript
How would you characterize telemedicine reimbursement in the oncology setting?
So far, reimbursement is going really well for telemedicine. We know that Medicare has put as part of their proposed fee schedule, the Physician Fee Schedule, reimbursement for telemedicine that will be robust. Only some aspects of radiation treatment supervision will go away after the global pandemic. So when Medicare reimbursement is strong, commercial payers tend to follow and we also were observing that. Now, there are state policies that vary by state regarding telemedicine, so each state has to make sure that they curate and advocate for appropriate telemedicine policy at the state level. But I think telemedicine is here to stay in ways that continue to be clinically meaningful to patient care.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
More Care Doesn't Equal Happier Patients in Traditional Medicare
March 17th 2025Data on care satisfaction, ease managing care, and out-of-pocket spending were the outcomes of interest for this new analysis that investigated the relationship between healthcare utilization and beneficiary experience within traditional Medicare.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More